Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Zhiwang Decoction + Methotrexate in Early RA
NCT05508815Phase 1Unknown
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of modified Zhiwang decoction in rheumatoid arthritis (RA) (2 arms), sponsored by Beijing University of Chinese Medicine. Primary endpoint: Disease Activity Score 28 based on Erythrocyte Sedimentation Rate at 12 weeks. Status: unknown.
02
Drugs
modified Zhiwang decoction
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05508815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508815.